NTRK1 and cancer: A study by James et al. specifically highlighted that SHC activation via the PI-3K pathway was involved in the mitogenic signaling of TCR and B cell antigen receptors and receptor tyrosine kinase families, suggesting that SHC1 may play a significant role in LUAD prognosis by influencing immune cell signaling and promoting cancer cell proliferation [74].